Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries
Awakn Life Sciences Corp
(OP:
AWKNF
)
0.0800
UNCHANGED
Streaming Delayed Price
Updated: 2:49 PM EST, Nov 4, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
0.0800
Bid (Size)
N/A (0)
Ask (Size)
N/A (0)
Prev. Close
0.0800
Today's Range
0.0800 - 0.0800
52wk Range
0.0422 - 0.1877
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Awakn Partners With University Of Nottingham For Preclinical Testing Of Psychoactive Therapy
October 15, 2024
Awakn Life Sciences partners with the University of Nottingham to advance in vivo testing of its aminoindane therapy for PTSD, with results expected by late 2024.
Via
Benzinga
Investors Back Awakn's Psychedelic Therapies, As Company Doubles Private Placement To $2M
September 18, 2024
Awakn Life Sciences expands its private placement to $2 million, closing the fourth tranche with $394,286 raised to accelerate research into addiction treatments.
Via
Benzinga
Performance
YTD
-27.60%
-27.60%
1 Month
-11.11%
-11.11%
3 Month
-6.43%
-6.43%
6 Month
-38.70%
-38.70%
1 Year
-44.83%
-44.83%
More News
Read More
Psychedelics Headlines: Dementia Prevention, Psychological Flexibility, Ancient Romans' Trips And More
April 17, 2024
Via
Benzinga
Psychedelics Headlines: Trauma-Informed Care, Valentine's Day & MDMA, Academics On Drugs And More
February 15, 2024
Via
Benzinga
Psychedelics Headlines: Anti-inflammatory Effects, Global Drug Survey, 'Synthetic Surprise,' UK's Harm Reduction Hub And More
January 26, 2024
Via
Benzinga
Psyched: Biden Approves Psychedelics Trials, RFK, Australia's First Legal Dedicated Clinic & More
December 27, 2023
Via
Benzinga
Awakn Life Sciences Enters Into Global Licensing Agreement For Sublingual Delivery Formulation
December 21, 2023
Via
Benzinga
Psyched: Ramaswamy Psychedelics For PTSD, UK Clinical Trials, Johns Hopkins Q&A And More
November 24, 2023
Via
Benzinga
Topics
Cannabis
Exposures
Cannabis
UK Psychedelics: Phase 3 Depression & Alcohol Addiction Trials, New London Center
November 15, 2023
Via
Benzinga
U.K.'s Prof. David Nutt Ranked World's Top Psychopharmacologist: More On His Contributions & Advocacy
October 15, 2023
Via
Benzinga
Psyched: Psilocybin Therapy For Depression, UK Rescheduling, US Policy Reform And More
September 11, 2023
Via
Benzinga
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Awakn Life Sciences Submits CTA For Phase III Alcohol Use Disorder Clinical Trial
September 06, 2023
Via
Benzinga
Psyched: Professional Practice Guidelines, DMT For Stroke, Dua Lipa &. Amanda Feilding, Clinical Results & More
August 14, 2023
Via
Benzinga
Psyched: Portugal Decriminalizes Synthetic Drugs, Anorexia And Psilocybin, LSD Microdosing, California & More
August 03, 2023
Via
Benzinga
Awakn Life Sciences Becomes Pure R&D Biotech After Sale Of Norway Clinics
August 01, 2023
Via
Benzinga
Awakn Life Sciences On Track With Phase 3 Trial To Research Substance Use Disorder
July 26, 2023
Via
Benzinga
Psyched: Australia's Innovative Program, Congressional Amendments, Therapy Reimbursement And More
July 11, 2023
Via
Benzinga
Awakn Life Sciences Sells London Clinics Business, Hopes To Divest Norwegian Unit Next
July 05, 2023
Via
Benzinga
Awakn Life Sciences Announces Closing Of Second Tranche And Upsizing Of Previous Private Placement
June 15, 2023
Via
Benzinga
Awakn To Focus On R&D Of Addiction Therapies, Moves Away From Ketamine Treatment For Alcoholism
June 12, 2023
Via
Benzinga
Psyched: Oregon And Colorado Regulations, MindMed CEO Discusses LSD Therapy, Mia Khalifa Enters Market & More
May 01, 2023
Via
Benzinga
Awakn's Q4 2023 And Annual Financials, +500% YoY Revenue Increase Following Network Expansion
April 28, 2023
Via
Benzinga
Psyched: LSD For Major Depression, Canada's Psilocybin Macrodose Trial, Treatments For Multiple Sclerosis And More
April 24, 2023
Via
Benzinga
Severe Alcohol Use Disorder Patients Will Try Ketamine Therapy At Awakn's New Phase 3 Study
April 19, 2023
Via
Benzinga
EXCLUSIVE: MDMA Therapy Experts Debate Upcoming Approval And Psychedelic Market Opps
April 19, 2023
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.